ALS (Amyotrophic Lateral Sclerosis) disease models and services
ALS, also known as motor neurone disease (MND), Lou Gehrig’s disease, and Charcot disease, is a fatal motor neuron disease marked by progressive weakness and muscle wasting.
ALS Disease model options
Transgenic SOD1 models
Transgenic TDP-43 Models
TDP-43 Seeding Models
View our comprehensive range of standardized and customized behavioural tests
ALS motor neuron disease
Pathology in the brain and spinal cord
Risk factors: C9orf72, SOD1, FUS, and TARDBP
Consequently, mice expressing the human protein with these mutations serve as highly promising models for evaluating therapeutics targeted at ALS.
The people behind the models
Jolien Beekens, PhD, Neurology Study Director
With in vitro screening methods available as a suited first step in your development process our team of experts have the experience to optimise your study design process.
Thomas Vogels, PhD, Neurology Study Director
Leads an expert team of scientists with vast experience in our Neurology models to help you choose the right model and guide your optimal study design. We provide the solution to accelerating your drug development.
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why Innoser has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
Need more information?
If you have any questions about how we can help accelerate your research,
then let us know